File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.jdiacomp.2018.09.001
- Scopus: eid_2-s2.0-85054438887
- PMID: 30314766
- WOS: WOS:000455073400004
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Circulating adipocyte fatty acid-binding protein levels predict the development of subclinical atherosclerosis in type 2 diabetes
| Title | Circulating adipocyte fatty acid-binding protein levels predict the development of subclinical atherosclerosis in type 2 diabetes |
|---|---|
| Authors | |
| Keywords | A-FABP Atherosclerosis Biomarker Diabetes Prediction |
| Issue Date | 2018 |
| Publisher | Elsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/jdiacomp |
| Citation | Journal of Diabetes and its Complications, 2018, v. 32 n. 12, p. 1100-1104 How to Cite? |
| Abstract | Objective:
The aim of this study was to investigate the prospective association of circulating adipocyte fatty acid-binding protein (A-FABP) levels with the development of subclinical atherosclerosis in patients with type 2 diabetes in an 8-year prospective study.
Methods:
A total of 170 patients with newly diagnosed type 2 diabetes were recruited in the study and 133 patients completed the follow-up of 8 years. Baseline plasma A-FABP levels were measured with enzyme-linked immunosorbent assays. The role of A-FABP in predicting the development of subclinical atherosclerosis over 8 years was analyzed using multiple logistic regression.
Results:
Of the 133 patients without subclinical atherosclerosis at baseline, a total of 100 had progressed to subclinical atherosclerosis over 8 years. Baseline A-FABP level was significantly higher in patients who had progressed to subclinical atherosclerosis at year 8 compared with ones who had not developed subclinical atherosclerosis after adjustment for sex (15.3 [12.1–23.2] versus 13.3 [10.0–18.9] ng/ml, P = 0.021). High baseline A-FABP level was an independent predictor for the development of subclinical atherosclerosis in patients with type 2 diabetes (odds ratio: 16.24, P = 0.022).
Conclusions:
Circulating A-FABP levels predict the development of subclinical atherosclerosis in type 2 diabetes patients. |
| Persistent Identifier | http://hdl.handle.net/10722/273931 |
| ISSN | 2021 Impact Factor: 3.219 2020 SCImago Journal Rankings: 1.022 |
| ISI Accession Number ID |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Xiao, Y | - |
| dc.contributor.author | Xiao, X | - |
| dc.contributor.author | Xu, A | - |
| dc.contributor.author | Chen, X | - |
| dc.contributor.author | Tang, W | - |
| dc.contributor.author | Zhou, Z | - |
| dc.date.accessioned | 2019-08-18T14:51:36Z | - |
| dc.date.available | 2019-08-18T14:51:36Z | - |
| dc.date.issued | 2018 | - |
| dc.identifier.citation | Journal of Diabetes and its Complications, 2018, v. 32 n. 12, p. 1100-1104 | - |
| dc.identifier.issn | 1056-8727 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/273931 | - |
| dc.description.abstract | Objective: The aim of this study was to investigate the prospective association of circulating adipocyte fatty acid-binding protein (A-FABP) levels with the development of subclinical atherosclerosis in patients with type 2 diabetes in an 8-year prospective study. Methods: A total of 170 patients with newly diagnosed type 2 diabetes were recruited in the study and 133 patients completed the follow-up of 8 years. Baseline plasma A-FABP levels were measured with enzyme-linked immunosorbent assays. The role of A-FABP in predicting the development of subclinical atherosclerosis over 8 years was analyzed using multiple logistic regression. Results: Of the 133 patients without subclinical atherosclerosis at baseline, a total of 100 had progressed to subclinical atherosclerosis over 8 years. Baseline A-FABP level was significantly higher in patients who had progressed to subclinical atherosclerosis at year 8 compared with ones who had not developed subclinical atherosclerosis after adjustment for sex (15.3 [12.1–23.2] versus 13.3 [10.0–18.9] ng/ml, P = 0.021). High baseline A-FABP level was an independent predictor for the development of subclinical atherosclerosis in patients with type 2 diabetes (odds ratio: 16.24, P = 0.022). Conclusions: Circulating A-FABP levels predict the development of subclinical atherosclerosis in type 2 diabetes patients. | - |
| dc.language | eng | - |
| dc.publisher | Elsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/jdiacomp | - |
| dc.relation.ispartof | Journal of Diabetes and its Complications | - |
| dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
| dc.subject | A-FABP | - |
| dc.subject | Atherosclerosis | - |
| dc.subject | Biomarker | - |
| dc.subject | Diabetes | - |
| dc.subject | Prediction | - |
| dc.title | Circulating adipocyte fatty acid-binding protein levels predict the development of subclinical atherosclerosis in type 2 diabetes | - |
| dc.type | Article | - |
| dc.identifier.email | Xu, A: amxu@hkucc.hku.hk | - |
| dc.identifier.authority | Xu, A=rp00485 | - |
| dc.description.nature | published_or_final_version | - |
| dc.identifier.doi | 10.1016/j.jdiacomp.2018.09.001 | - |
| dc.identifier.pmid | 30314766 | - |
| dc.identifier.scopus | eid_2-s2.0-85054438887 | - |
| dc.identifier.hkuros | 301602 | - |
| dc.identifier.volume | 32 | - |
| dc.identifier.issue | 12 | - |
| dc.identifier.spage | 1100 | - |
| dc.identifier.epage | 1104 | - |
| dc.identifier.isi | WOS:000455073400004 | - |
| dc.publisher.place | United States | - |
| dc.identifier.issnl | 1056-8727 | - |